Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Hidejiro Torigoe"'
Autor:
Yuki Monden, Dai Une, Hidejiro Torigoe, Tetsuya Isoda, Suzuka Kamaguchi, Kenji Yoshida, Yuji Hirami, Mikizo Nakai
Publikováno v:
Thoracic Cancer, Vol 15, Iss 7, Pp 578-581 (2024)
Abstract Intraluminal tumor in the azygos vein is a rare disease that can cause superior vena cava (SVC) syndrome. Radiotherapy and endovascular stenting with or without chemotherapy are reported to have a high clinical success rate for the managemen
Externí odkaz:
https://doaj.org/article/c590f352be094b7ba167b92ba76f4d5d
Autor:
Kei Namba, Shuta Tomida, Takehiro Matsubara, Yuta Takahashi, Eisuke Kurihara, Yusuke Ogoshi, Takahiro Yoshioka, Tatsuaki Takeda, Hidejiro Torigoe, Hiroki Sato, Kazuhiko Shien, Hiromasa Yamamoto, Junichi Soh, Kazunori Tsukuda, Shinichi Toyooka
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background In lung cancer, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor sensitizing mutations co-existing with rare minor EGFR mutations are known as compound mutations. These minor EGFR mutations can lead to acquired re
Externí odkaz:
https://doaj.org/article/0061557ff09a4c7f96518cb52de7af72
Autor:
Tatsuaki Takeda, Hiromasa Yamamoto, Hirotaka Kanzaki, Ken Suzawa, Takahiro Yoshioka, Shuta Tomida, Xiaojiang Cui, Ramachandran Murali, Kei Namba, Hiroki Sato, Hidejiro Torigoe, Mototsugu Watanabe, Kazuhiko Shien, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Yoshihisa Kitamura, Shinichiro Miyoshi, Toshiaki Sendo, Shinichi Toyooka
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0171356 (2017)
Overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 15-23% of breast cancers and these cancers are classified as HER2-positive breast cancer. Trastuzumab is the first-line targeted therapeutic drug for HER2-
Externí odkaz:
https://doaj.org/article/5b2dfa564e694a529e34914eeba067c8
Publikováno v:
The Journal of the Japanese Association for Chest Surgery. 36:791-798
Autor:
Shinichi Toyooka, Shuta Tomida, Junichi Soh, Hiromasa Yamamoto, Yusuke Ogoshi, Eisuke Kurihara, Tatsuaki Takeda, Takahiro Yoshioka, Hiroki Sato, Hidejiro Torigoe, Yuta Takahashi, Kazuhiko Shien, Kei Namba
Figure S1. Copy numbers of YES1 in osimertinib-resistant cell lines. Figure S2. PARP and MET expressions in MET-amplified osimertinib-resistant cell lines. Figure S3. Relative ALDH1A1 and ABCB1 expression levels using qRT-PCR in NSCLC EGFR-mutant cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ff1ea6d375b95269fc4714c2ddcdf7
https://doi.org/10.1158/1541-7786.22514668
https://doi.org/10.1158/1541-7786.22514668
Autor:
Shinichi Toyooka, Shuta Tomida, Junichi Soh, Hiromasa Yamamoto, Yusuke Ogoshi, Eisuke Kurihara, Tatsuaki Takeda, Takahiro Yoshioka, Hiroki Sato, Hidejiro Torigoe, Yuta Takahashi, Kazuhiko Shien, Kei Namba
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406ad954c83226f8b54a9c47af4a4fea
https://doi.org/10.1158/1541-7786.22514665.v1
https://doi.org/10.1158/1541-7786.22514665.v1
Autor:
Shinichi Toyooka, Shuta Tomida, Junichi Soh, Hiromasa Yamamoto, Yusuke Ogoshi, Eisuke Kurihara, Tatsuaki Takeda, Takahiro Yoshioka, Hiroki Sato, Hidejiro Torigoe, Yuta Takahashi, Kazuhiko Shien, Kei Namba
Table S1. ClearSeq Cancer Panel Gene List
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5462c45cd50100be83d938d436970157
https://doi.org/10.1158/1541-7786.22514662
https://doi.org/10.1158/1541-7786.22514662
Publikováno v:
Haigan. 59:378-383
Publikováno v:
Haigan. 59:147-150
Autor:
Tadahiko Shien, Shinichi Toyooka, Hidejiro Torigoe, Eisuke Kurihara, Junichi Soh, Kazuhiko Shien, Yuta Takahashi, Hiromasa Yamamoto, Yusuke Ogoshi, Mikio Okazaki, Takahiro Yoshioka, Ken Suzawa, Tatsuaki Takeda, Shuta Tomida, Hiroki Sato, Kei Namba
Publikováno v:
Anticancer Research. 39:1767-1775
Background The 90-kDa heat-shock protein (HSP90) is a chaperone protein expressed at high levels in cancer cells and is involved in the folding or stabilization of several client proteins, including epidermal growth factor receptor (EGFR). Ganetespib